Show simple item record

dc.contributor.authorJuma, FD
dc.date.accessioned2013-04-29T06:03:37Z
dc.date.available2013-04-29T06:03:37Z
dc.date.issued1987
dc.identifier.citationBr J Clin Pharmacol. 1987 Dec;24(6):809-11en
dc.identifier.urihttp://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/3440100
dc.identifier.urihttp://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/17407
dc.description.abstractThe pharmacokinetics of antipyrine were studied in 12 healthy volunteers and 10 patients of Kenya African origin with Hodgkin's lymphoma. The half-life of antipyrine was 12.2 +/- 1.3 h (mean + s.d.), while the apparent volume of distribution (V) was 0.67 +/- 0.11 l kg-1 (mean +/- s.d.) and the total body clearance was 40.7 +/- 3.2 ml kg-1 h-1 (mean +/- s.d.) in the healthy volunteers. The antipyrine half-life in the patients with advanced Hodgkin's lymphoma was 17.1 +/- 2.7 h (mean +/- s.d.). The apparent volume of distribution was 0.72 +/- 0.14 l kg-1 (mean +/- s.d.) which was larger than in healthy volunteers (P less than 0.05). The total body clearance was 30.3 +/- 9.4 ml kg-1 h-1 (mean + s.d.) and this was reduced compared with that in healthy volunteers (P less than 0.02). After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 +/- 1.3 h (mean +/- s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 +/- 0.07 l kg-1 (mean +/- s.d.) (P less than 0.05) while the total body clearance increased to 52.8 +/- 5.5 ml kg-1 h-1 (mean +/- s.d.) (P less than 0.01).en
dc.language.isoenen
dc.titleDisposition of antipyrine in African patients with Hodgkin's lymphoma.en
dc.typeArticleen
local.publisherDivision of Clinical Pharmacology, College of Health Sciences, University of Nairobi, Kenya.en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record